185 related articles for article (PubMed ID: 32939322)
1. Primary and metastatic breast tumors cross-talk to influence immunotherapy responses.
Oliver AJ; Keam SP; von Scheidt B; Zanker DJ; Harrison AJ; Tantalo DG; Darcy PK; Kershaw MH; Slaney CY
Oncoimmunology; 2020 Aug; 9(1):1802979. PubMed ID: 32939322
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific tumor microenvironments influence responses to immunotherapies.
Oliver AJ; Davey AS; Keam SP; Mardiana S; Chan JD; von Scheidt B; Beavis PA; House IG; Van Audernaerde JR; Darcy PK; Kershaw MH; Slaney CY
Clin Transl Immunology; 2019; 8(11):e1094. PubMed ID: 31768254
[TBL] [Abstract][Full Text] [Related]
3. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
[TBL] [Abstract][Full Text] [Related]
5. Primary tumor-induced immunity suppresses bone metastases of breast cancer in syngeneic immunocompetent mouse models.
Hiraga T; Nishida D; Horibe K
Bone; 2024 Jan; 178():116944. PubMed ID: 37863157
[TBL] [Abstract][Full Text] [Related]
6. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.
Marincola FM; Ettinghausen S; Cohen PA; Cheshire LB; Restifo NP; Mulé JJ; Rosenberg SA
J Immunol; 1994 Apr; 152(7):3500-13. PubMed ID: 8144931
[TBL] [Abstract][Full Text] [Related]
7. CD8
Monteiro AC; Bonomo A
Bone; 2021 Sep; 150():116014. PubMed ID: 34022456
[TBL] [Abstract][Full Text] [Related]
8. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
[TBL] [Abstract][Full Text] [Related]
9. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
Xu L; Xu W; Jiang Z; Zhang F; Chu Y; Xiong S
Cancer Biol Ther; 2009 Jan; 8(1):66-72. PubMed ID: 19029829
[TBL] [Abstract][Full Text] [Related]
10. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
11. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
[TBL] [Abstract][Full Text] [Related]
12. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W
Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000
[TBL] [Abstract][Full Text] [Related]
13. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
[TBL] [Abstract][Full Text] [Related]
14. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.
Wang XY; Kazim L; Repasky EA; Subjeck JR
Int J Cancer; 2003 Jun; 105(2):226-31. PubMed ID: 12673684
[TBL] [Abstract][Full Text] [Related]
15. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model.
Walser TC; Ma X; Kundu N; Dorsey R; Goloubeva O; Fulton AM
J Immunother; 2007; 30(5):490-8. PubMed ID: 17589289
[TBL] [Abstract][Full Text] [Related]
16. Nasal administration of recombinant
Battistoni A; Lantier L; di Tommaso A; Ducournau C; Lajoie L; Samimi M; Coënon L; Rivière C; Epardaud M; Hertereau L; Poupée-Beaugé A; Rieu J; Mévélec MN; Lee GS; Moiré N; Germon S; Dimier-Poisson I
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37192784
[TBL] [Abstract][Full Text] [Related]
17. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
18. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
19. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
